热门出版物 - 学术资源搜索

引用“”的文章STING pathway agonism as a cancer therapeutic

标题/作者	年份
Advances in immunotherapy for hepatocellular carcinoma B Sangro, P Sarobe, S Hervás-Stubbs, I Melero Nature reviews Gastroenterology & hepatology 18 (8), 525-543	2021
Structures and mechanisms in the cGAS-STING innate immunity pathway X Zhang, X Bai, ZJ Chen Immunity 53 (1), 43-53	2020
CD8+ T cell differentiation and dysfunction in cancer M Philip, A Schietinger Nature Reviews Immunology 22 (4), 209-223	2022
cGAS-STING, an important pathway in cancer immunotherapy M Jiang, P Chen, L Wang, W Li, B Chen, Y Liu, H Wang, S Zhao, L Ye, ... Journal of hematology & oncology 13, 1-11	2020
Trial watch: STING agonists in cancer therapy J Le Naour, L Zitvogel, L Galluzzi, E Vacchelli, G Kroemer Oncoimmunology 9 (1), 1777624	2020
Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment KC Lam, RE Araya, A Huang, Q Chen, M Di Modica, RR Rodrigues, ... Cell 184 (21), 5338-5356. e21	2021
Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy X Sun, Y Zhang, J Li, KS Park, K Han, X Zhou, Y Xu, J Nam, J Xu, X Shi, ... Nature nanotechnology 16 (11), 1260-1270	2021
Intratumoural administration and tumour tissue targeting of cancer immunotherapies I Melero, E Castanon, M Alvarez, S Champiat, A Marabelle Nature Reviews Clinical Oncology 18 (9), 558-576	2021
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy J Zheng, J Mo, T Zhu, W Zhuo, Y Yi, S Hu, J Yin, W Zhang, H Zhou, Z Liu Molecular cancer 19 (1), 1-19	2020
Germline genetic contribution to the immune landscape of cancer RW Sayaman, M Saad, V Thorsson, D Hu, W Hendrickx, J Roelands, ... Immunity 54 (2), 367-386. e8	2021
The continued advance of vaccine adjuvants–‘we can work it out’ DT O’Hagan, RN Lodaya, G Lofano Seminars in immunology 50, 101426	2020
Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity J Liang, H Wang, W Ding, J Huang, X Zhou, H Wang, X Dong, G Li, ... Science advances 6 (35), eabc3646	2020
Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas F Meric-Bernstam, RF Sweis, FS Hodi, WA Messersmith, RHI Andtbacka, ... Clinical Cancer Research 28 (4), 677-688	2022
Toll-like receptor 9 agonists in cancer L Karapetyan, JJ Luke, D Davar OncoTargets and therapy, 10039-10060	2020
Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies Y Liu, J Guo, L Huang Theranostics 10 (7), 3099	2020
Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response CS Garris, JJ Luke Clinical Cancer Research 26 (15), 3901-3907	2020
Immunogenic cell death in colon cancer prevention and therapy H Ruan, BJ Leibowitz, L Zhang, J Yu Molecular carcinogenesis 59 (7), 783-793	2020
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies RJ Walsh, RA Soo Therapeutic advances in medical oncology 12, 1758835920937902	2020
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance SC Jang, KD Economides, RJ Moniz, CL Sia, N Lewis, C McCoy, T Zi, ... Communications biology 4 (1), 497	2021
Bortezomib induces anti–multiple myeloma immune response mediated by cGAS/STING pathway activation A Gulla, E Morelli, MK Samur, C Botta, T Hideshima, G Bianchi, M Fulciniti, ... Blood cancer discovery 2 (5), 468-483	2021

1 - 20

计算机程序会自动估算并确定日期和引用次数。